JMP Securities Maintains Market Outperform on Macrogenics, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reaffirmed a Market Outperform rating on Macrogenics (NASDAQ:MGNX) and increased the price target from $10 to $16, indicating a positive outlook on the company's stock.
January 24, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst has maintained a Market Outperform rating on Macrogenics and raised the price target from $10 to $16, suggesting a strong bullish sentiment on the stock.
The increase in price target by JMP Securities is a strong positive endorsement of Macrogenics' prospects, likely leading to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100